These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33072585)

  • 21. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
    Wang H; Chen S; Meng D; Wu C; Zhu J; Jiang M; Ning J; Wu S; Wu L; Li J; Chen B; Zhao S; Li W; Yu J; Fang Q; Zhu J; Zhao W; He Y; Zhou C
    Onco Targets Ther; 2021; 14():2953-2965. PubMed ID: 33976553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.
    Lu Z; Chen H; Li S; Gong J; Li J; Zou J; Wu L; Yu J; Han W; Sun H; Jiao X; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32792358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
    Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and
    Yang S; Yu X; Fan Y; Shi X; Jin Y
    J Cancer; 2018; 9(16):2930-2937. PubMed ID: 30123361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
    Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
    Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive Value of Max's Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Qu Y; Wang C; Liu L; Li S; Zhang X; Ma Z; Bai H; Wang J
    Front Cell Dev Biol; 2021; 9():728647. PubMed ID: 34733843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival in metastatic microsatellite-stable colorectal cancer correlated with tumor mutation burden and mutations identified by next-generation sequencing.
    Taflin N; Sandow L; Thawani R; Ye S; Kardosh A; Corless CL; Chen EY
    J Gastrointest Oncol; 2024 Apr; 15(2):681-688. PubMed ID: 38756628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
    Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
    Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
    J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of
    Jia M; Yao L; Yang Q; Chi T
    Front Oncol; 2020; 10():168. PubMed ID: 32154170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
    Heeke S; Benzaquen J; Long-Mira E; Audelan B; Lespinet V; Bordone O; Lalvée S; Zahaf K; Poudenx M; Humbert O; Montaudié H; Dugourd PM; Chassang M; Passeron T; Delingette H; Marquette CH; Hofman V; Stenzinger A; Ilié M; Hofman P
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of immunotherapy in
    Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
    Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
    Sun Y; Li Z; Jian H; Xia L; Lu S
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types.
    Asleh K; Ouellette RJ
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
    Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
    Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.